Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b)
On May 11, 2020, Lesley Ann Calhoun, Senior Vice President, Finance and principal accounting officer of Global Blood Therapeutics, Inc. (the “Company”), delivered notice of her resignation from these positions and from her employment with the Company, to be effective on May 29, 2020 (the “Calhoun Resignation”), in order to pursue a leadership opportunity with a privately-held healthcare company. Ms. Calhoun’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, financial statements, internal controls, auditors, policies or practices.
(c)
On May 13, 2020, the Board of Directors of the Company appointed Jeffrey Farrow, the Company’s Chief Financial Officer, as principal accounting officer of the Company, effective upon the Calhoun Resignation.
Mr. Farrow, 58, has served as the Company’s Chief Financial Officer and principal financial officer since April 2016. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 where he was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).
There are no arrangements or understandings between Mr. Farrow and any other persons pursuant to which he was appointed as principal accounting officer of the Company, and Mr. Farrow has no family relationship with any director or executive officer of the Company. Mr. Farrow is not a party to any current or proposed transaction with the Company for which disclosure would be required under Item 404(a) of Regulation S-K.